trans-3-hexenoyl raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-01. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
In order for this application to be successful, assorted surface functional groups are necessary and can be added either by the co-condensation process during preparation or by post surface modification. The high surface area of silica nanoparticles allows them to carry much larger amounts of the desired drug than through conventional methods like polymers and liposomes. It allows for site specific targeting, especially in the treatment of cancer. Once the particles have reached their destination, they can act as a reporter, release a compound, or be remotely heated to damage biological structures in close proximity. Targeting is typically accomplished by modifying the surface of the nanoparticle with a chemical or biological compound. They accumulate at tumor sites through Enhanced Permeability Retention (EPR), where the tumor vessels accelerate the delivery of the nanoparticles directly into the tumor. The porous shell of the silica allows control over the rate at which the drug diffuses out of the nanoparticle. The shell can be modified to have an affinity for the drug, or even to be triggered by pH, heat, light, salts, or other signaling molecules. Silica nanoparticles are also used in bio imaging because they can accommodate fluorescent/MRI/PET/ SPECT contrast agents and drug/DNA molecules to their adaptable surface and pores. This is made possible by using the silica nanoparticle as a vector for the expression of fluorescent proteins.
=== La–Li === Irving Langmuir (1881–1957), American chemist, physicist, 1932 Nobel Prize in Chemistry for work in surface chemistry Auguste Laurent (1807–1853), French chemist who discovered trichloroethylene, anthracene, phthalic acid, and carbolic acid Paul Lauterbur (1929–2007), American chemist, Nobel Prize in Physiology or Medicine (2003) work which that the development of magnetic resonance imaging possible Antoine Lavoisier (1743–1794), French chemist who recognized oxygen and hydrogen as elements Nicolas Leblanc (1742–1806), French chemist and surgeon who discovered how to manufacture soda ash from common salt Henri Louis Le Chatelier (1850–1936), French chemist known for Le Chatelier's principle, which allows prediction of the effect of a changing condition on a system in chemical equilibrium Yuan T. Lee (born 1936), Taiwanese chemist, 1986 Nobel Prize in Chemistry for contributions to the development of reaction dynamics Valery Legasov (1936–1988), Soviet inorganic chemist known for his position as head of the Chernobyl Commission for the Chernobyl Disaster Jean-Marie Lehn (born 1939), French chemist, 1987 Nobel Prize in Chemistry for the synthesis of cryptands Marko Leko (1853–1932), Serbian chemist known for work on the nature of ammonium chloride Luis Federico Leloir (1906–1987), Argentine biochemist and winner of the 1970 Nobel Prize in Chemistry Raymond Lemieux (1920–2000), Canadian organic chemist, Wolf Prize in Chemistry Gilbert Newton Lewis (1875–1946), American chemist and first Dean of the Berkeley College of Chemistry
== Medical uses == Uses include angiography (imaging of blood vessels, including those of the brain and heart), arthrography (imaging of joints), urography (imaging of the urinary system), hysterosalpingography (imaging of the uterus and fallopian tubes), imaging of the gastrointestinal tract, and endoscopic retrograde cholangiopancreatography (ERCP; imaging of the biliary and pancreatic ducts).
==== Pulmonary tissues ==== Lung tissue engineering focuses on developing functional respiratory structures to treat end-stage pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). Due to the complex, highly vascularized three-dimensional architecture of the lung, which comprises over forty distinct cell types and a delicate alveolar-capillary basement membrane, whole-organ biofabrication typically relies on decellularized donor lung scaffolds. This process strips away immunogenic cellular material while preserving the native extracellular matrix geometry and mechanical compliance required for ventilation. Research strategies prioritize the multi-lineage recellularization of these scaffolds using patient-specific induced pluripotent stem cells (iPSCs) differentiated into alveolar epithelial cells (type I and II) and microvascular endothelial cells. Additionally, biomimetic microfluidic platforms, or "lung-on-a-chip" models, are utilized to study cellular shear stress and gas-exchange dynamics, serving as precursors to transplantable bioartificial lung devices.
Sources: en.wikipedia.org
From 2011, new cars should have brake assist system in the EU, according to The Pedestrian Protection Regulation (EC) 78/2009. Starting in 2012, all cars under 10,000 lbs. sold in the US are required to have Electronic Stability Control. In 2014, ESP (Electronic Stability Program) and TPMS became mandatory in the European Union, with also the driver seat belt reminder and the ISOFIX system, under General Safety Regulation (EC) No 661/2009. In 2015, recognizing that safer roads are a shared responsibility, Together for Safer Roads (TSR) was formally launched to align the private sector's road safety efforts with the United Nations Decade of Action for Road Safety. In 2016 and 2017, ABS became mandatory on motorcycles in the EU. In 2018, eCall became mandatory in the EU, and reverse camera in the US. In 2019, the EU legislated to revise the General Safety Regulation (GSR), the revision includes the following automotive safety features:
Knowledge base annotation is done based on the information of gene attribute, protein function and its metabolism. In this type of annotation more emphasis is given to genetic variation that disrupts the protein function domain, protein-protein interaction and biological pathway. The non-coding region of genome contain many important regulatory elements including promoter, enhancer and insulator, any kind of change in this regulatory region can change the functionality of that protein. The mutation in DNA can change the RNA sequence and then influence the RNA secondary structure, RNA binding protein recognition and miRNA binding activity. This method mainly identifies variant function based on the information whether the variant loci are in the known functional region that harbor genomic or epigenomic signals. The function of non-coding variants are extensive in terms of the affected genomic region and they involve in almost all processes of gene regulation from transcriptional to post translational level
As the longest-lived radioactive isotope ruthenium-106 has a half-life of only 373.59 days, it has been suggested that the ruthenium and palladium in PUREX raffinate should be used as a source of the metals after allowing the radioactive isotopes to decay. After ten half-life cycles have passed, over 99.9% of any radioisotope is stable. For Ru-106 this is 3,735.9 days or about 10 years.
females age 12 to 21 may have iron deficiency (27 June), researchers show how bird flu could mutate to overcome a human antiviral protein to start another pandemic (28 June), shortages of medications – including some against cancer – are reported across countries, articles in science outlets like Nature suggest contemporary viral concerns about hypothetical existential risk of AI "plays into the tech companies' agenda" – partly in the form of 'criti-hype' – and that this "hinders effective regulation of the societal harms AI is causing right now" and in the near-future. Promising results of therapeutic candidates are reported: first phase 3 trialed chikungunya vaccine (VLA1553) (12 June), mice-tested inoculation against a potential infectious contributor to endometriosis (14 June), new evidence regarding still-unclear vaginal seeding interventions (15 June), phase 2 trialed orforglipron against obesity (23 June), mice-tested gene-therapy against hearing loss (28 June).
=== Molecular mechanisms of action === Quisqualic acid is functionally similar to glutamate, which is an endogenous agonist of glutamate's receptors. It functions as a neurotransmitter in insect neuromuscular junction and CNS. It passes the blood brain barrier and binds to cell surface receptors AMPA and Kainate receptors in the brain. AMPA receptor is a type of ionotropic glutamate receptor coupled to ion channels and when bound to a ligand, it modulates the excitability by gating the flow of calcium and sodium ions into the intracellular domain. On the other hand, kainate receptors are less understood than AMPA receptors. Although, the function is somewhat similar: the ion channel permeates the flow of sodium and potassium ions, and to a lower extent the Calcium ions. As mentioned, binding of quisqualic acid to these receptors leads to an influx of calcium and sodium ions into the neurons, which triggers downstream signaling cascades. Calcium signaling involves protein effectors such as kinases (CaMK, MAPK/ERKs), CREB-transcription factor and various phosphatases. It regulates gene expression and may modify the properties of the receptors. Sodium and calcium ions together generate an excitatory postsynaptic potential (EPSP) that triggers action potentials. It's worthwhile to mention that overactivation of glutamate receptors and kainate receptors lead to excitotoxicity and neurological damage. A greater dose of quisqualic acid over activates these receptors that can induce seizures, due to prolonged action potentials firing the neurons.
Sources: en.wikipedia.org
2 K + H2 → 2 KH It is a white, pyrophoric solid that finds some use as a base. All of the halides salts are well known: potassium fluoride (KF), potassium chloride (KCl), potassium bromide (KBr), and potassium iodide (KI). Four oxides of potassium are well studied: potassium oxide (K2O), potassium peroxide (K2O2), potassium superoxide (KO2) and potassium ozonide (KO3). These species all hydrolyze (react with water) to give potassium hydroxide. Similarly an extensive array of sulfides, selenides, and tellurides are well characterized. Although such simple salts are typically white and diamagnetic, KO2 is something of an exception, being deep yellow and paramagnetic.
Ribose 5-phosphate (R5P) is both a product and an intermediate of the pentose phosphate pathway. The last step of the oxidative reactions in the pentose phosphate pathway is the production of ribulose 5-phosphate. Depending on the body's state, ribulose 5-phosphate can reversibly isomerize to ribose 5-phosphate. Ribulose 5-phosphate can alternatively undergo a series of isomerizations as well as transaldolations and transketolations that result in the production of other pentose phosphates as well as fructose 6-phosphate and glyceraldehyde 3-phosphate (both intermediates in glycolysis). The enzyme ribose-phosphate diphosphokinase converts ribose-5-phosphate into phosphoribosyl pyrophosphate.
== Balanced salt solutions == Alsever's solution Earle's balanced salt solution (EBSS) Gey's balanced salt solution (GBSS) Hanks' balanced salt solution (HBSS) (Dulbecco's) Phosphate buffered saline (PBS) Puck's balanced salt solution Ringer's balanced salt solution (RBSS) Simm's balanced salt solution (SBSS) TRIS-buffered saline (TBS) Tyrode's balanced salt solution (TBSS)
Before they can stop her, Mossman teleports herself and Eli to the Citadel. The teleporter explodes moments after Gordon and Alyx use it to escape Nova Prospekt. Returning to Kleiner's lab, Gordon and Alyx learn that the teleporter malfunctioned and that a week has passed, during which time the Resistance has used the attack on Nova Prospekt to launch an armed rebellion against the Combine. Aided by Barney and Dog, Gordon fights his way to the Citadel. Inside, a security system vaporizes his weapons but inadvertently super-charges the gravity gun; this helps Gordon climb the tower. He is captured and taken in a transport pod to Breen's private office, near the Citadel's apex, where he and Mossman are waiting with Eli and Alyx as captives. Breen reveals that he plans to use them as leverage to negotiate with the Combine, contradicting what he had told Mossman. Angered, Mossman frees the captives and Breen attempts to escape using a teleporter. Gordon destroys the reactor and Breen falls into the abyss. Moments after the reactor explodes, the G-Man reappears and freezes time, praises Gordon's actions, and returns him to stasis.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.